Table 1.
UK licensed monoclonal antibodies
| Name | Type of antibody | Target | Licensed indication |
| Infliximab (Remicade) | Human–mouse chimaera IgG1 | TNF-α | Refractory Crohn's, Crohn's fistulas, refractory rheumatoid arthritis |
| Palivizumab (Synagis) | Humanised IgG1 | F protein on RSV | Prophylaxis, RSV in premature infants or brochopulmonary dysplasia |
| Abciximab (ReoPro) | Human–mouse chimaera | Platelet glycoprotein IIb/IIIa | High risk coronary intervention |
| Rituximab (MabThera) | Human–mouse chimaera IgG1 | CD20 | Refractory low grade or follicular B cell lymphoma |
| Basiliximab (Simulect) | Human–mouse chimaera IgG1K | IL-2 receptor α chain | Prophylaxis of acute rejection in allogeneic renal transplantation |
| Daclizumab (Zenapax) | Humanised IgG1 | IL-2 receptor α | As Basiliximab |
| Trastuzumab (Herceptin) | Humanised IgG1 | HER 2 growth receptor | Relapsed HER2 (high) breast malignancy |
IL-2, interleukin 2; TNF-α, tumour necrosis factor α; RSV, respiratory syncitial virus.